|

BTC-Ag-T (ACH-AgT001) Clinical Trials

1 actively recruiting trial

Also known as: CD160-Ag-T; ACH-AgT001

Pipeline

Phase 1: 1

Top Sponsors

  • Shanghai Zhongshan Hospital1

Indications

  • Cholangiocarcinoma, Intrahepatic1
  • Cholangiocarcinoma, Perihilar1
  • Cholangiocarcinoma, Extrahepatic1
  • Biliary Tract Neoplasms1
  • Gallbladder Cancer1

Other1 trial

Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.